🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Bordeaux
NCT06247150 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD). The latter occurs in nearly 50% of patients and its pathogenesis remains poorly understood. Previous translational studies have delineated biological immune dysregulation involved in cGVHD and facilitated the development of new drug and therapeutic strategies. New aspects of T and B cells collaboration in the context of cGVHD using blood description of a key player called TFH, classicaly involved in germinal center reaction, were previously uncovered (Forcade et al, Blood 2016). Previous studies in the context of auto-immune inflammation (lupus nephritis) or organ transplant rejection, suggested that target tissue could contain accessory lymphoid structures (TLS). The description of such structures in cGVHD targe

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient \> 18 yo ; * Having undergone an allogeneic stem cell tranplant ; * 2 groups of patients will be eligible * showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion * in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ; * in the case of recurrent cGVHD, steroid dose has to be below 15mg/day of Prednisone ; * Having read, understood and signed an informed consent of the study; * With social security affiliation; Exclusion Criteria: * Patient below 18 yo or unable to give consent ; * Systemic therapy using steroids over 15mg/d of Prednisone ; and/or the use of other systemic agent introduced in the last month ; * Haemorrhagic risk of biopsy anticipated ; * Absence of patient agreement for the study
💊

What it tests

  • Additional blood sample
  • cGVHD target tissue biopsy
📍

Where

1 site
CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire
Pessac, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy